Dysphagia · Patients with gastro‐oesophageal reflux disease (GORD) in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
(5 years or more) · Patients with gastro‐oesophageal reflux disease (GORD) in adults
It is very uncertain whether laparoscopic fundoplication changes (5 years or more) compared with medical management (very low certainty).
1 finding from 1 review
Heartburn · Patients with gastro‐oesophageal reflux disease (GORD) in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reflux · Patients with gastro‐oesophageal reflux disease (GORD) in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Angina reduction ‐ NYHA scale Decrease in two angina classes or more · patients with refractory angina
Transmyocardial laser revascularization may leads to higher angina reduction Decrease in two angina classes or more compared with medical treatment (low certainty).
2 findings from 1 review
Angina reduction ‐ CCS score Decrease in two angina classes or more · patients with refractory angina
Transmyocardial laser revascularization may leads to higher angina reduction ‐ CCS score Decrease in two angina classes or more compared with medical treatment (low certainty).
1 finding from 1 review
Overall mortality · patients with refractory angina
Transmyocardial laser revascularization showed no clear difference in overall mortality compared with medical treatment (high certainty).
1 finding from 1 review
Early postoperative mortality Deaths in the 30 days after surgery · patients with refractory angina
Transmyocardial laser revascularization showed no clear difference in early postoperative mortality Deaths in the 30 days after surgery compared with medical treatment (high certainty).
1 finding from 1 review
Exercise tolerance Minutes · patients with refractory angina
1 finding from 1 review
Primary outcome measure: composite of recurrent stroke (non‐fatal or fatal) or transient ischemic attack (TIA) · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in primary outcome measure: composite of recurrent stroke (non‐fatal or… compared with medical therapy (low certainty).
1 finding from 1 review
Time‐to‐event analyses for composite of recurrent stroke or TIA · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in time‐to‐event analyses for composite of recurrent stroke or TIA compared with medical therapy (low certainty).
1 finding from 1 review
Time‐to‐event analyses for composite of recurrent stroke or TIA stratified by the type of device studied ‐ Amplatzer PFO occluder · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in time‐to‐event analyses for composite of recurrent stroke or TIA… compared with medical therapy (low certainty).
1 finding from 1 review
CI: Confidence interval;HR: hazard ratio · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary outcome measure: composite of recurrent stroke (non‐fatal or fatal) or transient ischemic attack (TIA) stratified by the type of device ‐ Amplatzer PFO occluder · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in primary outcome measure: composite of recurrent stroke (non‐fatal or… compared with medical therapy (low certainty).
1 finding from 1 review
Recurrent events: fatal or non‐fatal (same type of stroke, i.e. ischaemic or haemorrhagic) · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in primary outcome measure: recurrent stroke (non‐fatal or fatal) compared with medical therapy (low certainty).
1 finding from 1 review
Primary outcome measure: recurrent stroke (non‐fatal or fatal) stratified by the type of device studied ‐ Amplatzer PFO occluder · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in primary outcome measure: recurrent stroke (non‐fatal or fatal)… compared with medical therapy (low certainty).
1 finding from 1 review
Death from any cause (secondary outcome 3) · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in secondary outcome: all‐cause mortality at the end of compared with medical therapy (low certainty).
1 finding from 1 review
Secondary outcome:total serious adverse events at the end of · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in secondary outcome:total serious adverse events at the end of compared with medical therapy (low certainty).
1 finding from 1 review
Secondary outcome: the incidence of atrial fibrillation · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC probably leads to higher secondary outcome: the incidence of atrial fibrillation compared with medical therapy (moderate certainty).
1 finding from 1 review
Time‐to‐event analyses for recurrent stroke · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in time‐to‐event analyses for recurrent stroke compared with medical therapy (low certainty).
1 finding from 1 review